Home The Word Brain	My Amedeo FAQ Privacy About
	Amedeo C49 English + 你好 (nǐ hǎo) = limitless possibilities. Start learning Mandarin Chinese today—for free, forever. Amedeo C49 is completely free, for life. Next week: +49.

Autoimmune Disorders

Free Subscription Articles published in N Engl J Med Retrieve available abstracts of 102 articles: HTML format

Single Articles

October 2025
1. VAN VOLLENHOVEN RF, Wang L, Merrill JT, Liu Y, et al
   A Phase 3 Trial of Telitacicept for Systemic Lupus Erythematosus.
   N Engl J Med. 2025;393:1475-1485.
   PubMed     Abstract available
   
   
   
2. BUCCI L, Boltz S, Hagen M, Tur C, et al
   BCMA T-Cell Engager Therapy in Patients with Refractory Autoimmune Disease.
   N Engl J Med. 2025;393:1544-1547.
   PubMed    
   
   
   September 2025
3. WANG Q, Xiao ZX, Zheng X, Wang G, et al
   In Vivo CD19 CAR T-Cell Therapy for Refractory Systemic Lupus Erythematosus.
   N Engl J Med. 2025 Sep 17. doi: 10.1056/NEJMc2509522.
   PubMed    
   
   
   
4. CARLSSON PO, Hu X, Scholz H, Ingvast S, et al
   Survival of Transplanted Allogeneic Beta Cells with No Immunosuppression.
   N Engl J Med. 2025;393:887-894.
   PubMed     Abstract available
   
   
   August 2025
5. TRAPNELL BC, Inoue Y, Bonella F, Wang T, et al
   Phase 3 Trial of Inhaled Molgramostim in Autoimmune Pulmonary Alveolar Proteinosis.
   N Engl J Med. 2025;393:764-773.
   PubMed     Abstract available
   
   
   
6. SEYMOUR JF
   GM-CSF in Autoimmune Pulmonary Alveolar Proteinosis.
   N Engl J Med. 2025;393:812-816.
   PubMed    
   
   
   July 2025
7. FURIE RA, Rovin BH, Pendergraft WF 3rd
   Efficacy and Safety of Obinutuzumab in Active Lupus Nephritis. Reply.
   N Engl J Med. 2025;393:410.
   PubMed    
   
   
   
8. DE FREMONT GM, Le Guern V, Costedoat-Chalumeau N
   Efficacy and Safety of Obinutuzumab in Active Lupus Nephritis.
   N Engl J Med. 2025;393:409-410.
   PubMed    
   
   
   
9. KARASSA FB
   Efficacy and Safety of Obinutuzumab in Active Lupus Nephritis.
   N Engl J Med. 2025;393:409.
   PubMed    
   
   
   
10. SAHUTOGLU T
    Efficacy and Safety of Obinutuzumab in Active Lupus Nephritis.
    N Engl J Med. 2025;393:408-409.
    PubMed    
    
    
    
11. ANGELETTI A, Marasa M, Cravedi P
    Efficacy and Safety of Obinutuzumab in Active Lupus Nephritis.
    N Engl J Med. 2025;393:408.
    PubMed    
    
    
    June 2025
12. REICHMAN TW, Markmann JF, Odorico J, Witkowski P, et al
    Stem Cell-Derived, Fully Differentiated Islets for Type 1 Diabetes.
    N Engl J Med. 2025 Jun 20. doi: 10.1056/NEJMoa2506549.
    PubMed     Abstract available
    
    
    
13. WOLFE GI, Shelly S
    Myasthenia Gravis - Redemption for B-Cell Depletion.
    N Engl J Med. 2025;392:2382-2384.
    PubMed    
    
    
    
14. ZHANG L, Gao Z, Pan H, Li R, et al
    BCMA-Targeted T-Cell Engager for Autoimmune Hemolytic Anemia after CD19 CAR T-Cell Therapy.
    N Engl J Med. 2025;392:2282-2284.
    PubMed    
    
    
    May 2025
15. KOSTER MJ, Warrington KJ
    Upadacitinib - An Up-and-Comer for Treatment of Giant-Cell Arteritis.
    N Engl J Med. 2025;392:2062-2064.
    PubMed    
    
    
    
16. BARRATT J, Perkovic V, Rizk DV
    Alternative Complement Pathway, Iptacopan, and IgA Nephropathy. Reply.
    N Engl J Med. 2025;392:1976.
    PubMed    
    
    
    
17. ANGELETTI A, Marasa M, Cravedi P
    Alternative Complement Pathway, Iptacopan, and IgA Nephropathy.
    N Engl J Med. 2025;392:1976.
    PubMed    
    
    
    
18. POPPELAARS F, Faria B, Thurman JM
    Alternative Complement Pathway, Iptacopan, and IgA Nephropathy.
    N Engl J Med. 2025;392:1975.
    PubMed    
    
    
    
19. CALABRESI PA
    Progress toward Mitigating Disability Progression in Multiple Sclerosis.
    N Engl J Med. 2025;392:1966-1968.
    PubMed    
    
    
    
20. HOSHINO Y, Okamoto K, Ito N
    More on Acquired Osteomalacia and Autoantibodies against PHEX. Reply.
    N Engl J Med. 2025;392:1871-1872.
    PubMed    
    
    
    
21. MINISOLA S, Pepe J, Cipriani C
    More on Acquired Osteomalacia and Autoantibodies against PHEX.
    N Engl J Med. 2025;392:1871.
    PubMed    
    
    
    April 2025
22. FAVA A
    To B or Not to B - the Role of B-Cell Depletion in Lupus Nephritis.
    N Engl J Med. 2025;392:1545-1547.
    PubMed    
    
    
    
23. FOX RJ, Bar-Or A, Traboulsee A, Oreja-Guevara C, et al
    Tolebrutinib in Nonrelapsing Secondary Progressive Multiple Sclerosis.
    N Engl J Med. 2025 Apr 8. doi: 10.1056/NEJMoa2415988.
    PubMed     Abstract available
    
    
    
24. OH J, Arnold DL, Cree BAC, Ionete C, et al
    Tolebrutinib versus Teriflunomide in Relapsing Multiple Sclerosis.
    N Engl J Med. 2025 Apr 8. doi: 10.1056/NEJMoa2415985.
    PubMed     Abstract available
    
    
    
25. NOWAK RJ, Benatar M, Ciafaloni E, Howard JF Jr, et al
    A Phase 3 Trial of Inebilizumab in Generalized Myasthenia Gravis.
    N Engl J Med. 2025 Apr 8. doi: 10.1056/NEJMoa2501561.
    PubMed     Abstract available
    
    
    
26. BLOCKMANS D, Penn SK, Setty AR, Schmidt WA, et al
    A Phase 3 Trial of Upadacitinib for Giant-Cell Arteritis.
    N Engl J Med. 2025 Apr 2. doi: 10.1056/NEJMoa2413449.
    PubMed     Abstract available
    
    
    March 2025
27. STONE JH, Khosroshahi A, Zhang W, Della Torre E, et al
    Inebilizumab for Treatment of IgG4-Related Disease.
    N Engl J Med. 2025;392:1168-1177.
    PubMed     Abstract available
    
    
    February 2025
28. WANG JJ, Warkentin TE, Schonborn L, Wheeler MB, et al
    VITT-like Monoclonal Gammopathy of Thrombotic Significance.
    N Engl J Med. 2025 Feb 12. doi: 10.1056/NEJMoa2415930.
    PubMed     Abstract available
    
    
    
29. FURIE RA, Rovin BH, Garg JP, Santiago MB, et al
    Efficacy and Safety of Obinutuzumab in Active Lupus Nephritis.
    N Engl J Med. 2025 Feb 7. doi: 10.1056/NEJMoa2410965.
    PubMed     Abstract available
    
    
    January 2025
30. HOSHINO Y, Okamoto K, Ogawa T, Kato H, et al
    Acquired Osteomalacia Associated with Autoantibodies against PHEX.
    N Engl J Med. 2025;392:513-515.
    PubMed    
    
    
    October 2024
31. PERKOVIC V, Barratt J, Rovin B, Kashihara N, et al
    Alternative Complement Pathway Inhibition with Iptacopan in IgA Nephropathy.
    N Engl J Med. 2024 Oct 25. doi: 10.1056/NEJMoa2410316.
    PubMed     Abstract available
    
    
    
32. INGELFINGER JR
    Way Stations in Progress - Burgeoning Treatment Options for IgA Nephropathy.
    N Engl J Med. 2024 Oct 25. doi: 10.1056/NEJMe2413288.
    PubMed    
    
    
    
33. HEERSPINK HJL, Jardine M, Kohan DE, Lafayette RA, et al
    Atrasentan in Patients with IgA Nephropathy.
    N Engl J Med. 2024 Oct 25. doi: 10.1056/NEJMoa2409415.
    PubMed     Abstract available
    
    
    
34. CHANTRAPITAK J, Chuamanochan M
    Intertriginous Rash in Secondary Syphilis.
    N Engl J Med. 2024;391:e28.
    PubMed    
    
    
    
35. TOMAS NM, Hengel FE, Huber TB
    Autoantibodies Targeting Nephrin in Podocytopathies. Reply.
    N Engl J Med. 2024;391:1367-1368.
    PubMed    
    
    
    
36. BRUSCHI M, Angeletti A, Ghiggeri GM
    Autoantibodies Targeting Nephrin in Podocytopathies.
    N Engl J Med. 2024;391:1366.
    PubMed    
    
    
    
37. BERG AH, Karumanchi SA
    Autoantibodies Targeting Nephrin in Podocytopathies.
    N Engl J Med. 2024;391:1365-1366.
    PubMed    
    
    
    
38. GLEESON PJ, Monteiro RC
    Autoantibodies Targeting Nephrin in Podocytopathies.
    N Engl J Med. 2024;391:1365.
    PubMed    
    
    
    September 2024
39. RUSSO G, Alipour Tehrany Y
    Discoid Lupus Erythematosus.
    N Engl J Med. 2024;391:e24.
    PubMed    
    
    
    
40. SALVARANI C, Hunder GG, Brown RD Jr
    Primary Central Nervous System Vasculitis.
    N Engl J Med. 2024;391:1028-1037.
    PubMed    
    
    
    
41. HAGEN M, Bucci L, Boltz S, Nothling DM, et al
    BCMA-Targeted T-Cell-Engager Therapy for Autoimmune Disease.
    N Engl J Med. 2024;391:867-869.
    PubMed    
    
    
    
42. ALEXANDER T, Kronke J, Cheng Q, Keller U, et al
    Teclistamab-Induced Remission in Refractory Systemic Lupus Erythematosus.
    N Engl J Med. 2024;391:864-866.
    PubMed    
    
    
    August 2024
43. GRIFFIN H, Ceron-Gutierrez L, Gharahdaghi N, Ebrahimi S, et al
    Neutralizing Autoantibodies against Interleukin-10 in Inflammatory Bowel Disease.
    N Engl J Med. 2024;391:434-441.
    PubMed     Abstract available
    
    
    July 2024
44. LI M, Zhang Y, Jiang N, Ning C, et al
    Anti-CD19 CAR T Cells in Refractory Immune Thrombocytopenia of SLE.
    N Engl J Med. 2024;391:376-378.
    PubMed    
    
    
    
45. WANG WY, Lin MC
    Chilblain Lupus Erythematosus.
    N Engl J Med. 2024;391:e6.
    PubMed    
    
    
    
46. CHENG A, Holland SM
    Anti-Interleukin-23 Autoantibodies in Adult-Onset Immunodeficiency. Reply.
    N Engl J Med. 2024;391:189-190.
    PubMed    
    
    
    
47. ROSMARIN D, Amara S, Lebwohl M
    Anti-Interleukin-23 Autoantibodies in Adult-Onset Immunodeficiency.
    N Engl J Med. 2024;391:189.
    PubMed    
    
    
    
48. COHEN JM, Damsky W
    Anti-Interleukin-23 Autoantibodies in Adult-Onset Immunodeficiency.
    N Engl J Med. 2024;391:188-189.
    PubMed    
    
    
    
49. FEREDJ E, Cobat A, Casanova JL
    Anti-Interleukin-23 Autoantibodies in Adult-Onset Immunodeficiency.
    N Engl J Med. 2024;391:187-188.
    PubMed    
    
    
    June 2024
50. MANRIQUE-ACEVEDO C, Hirsch IB, Eckel RH
    Prevention of Cardiovascular Disease in Type 1 Diabetes. Reply.
    N Engl J Med. 2024;390:2227.
    PubMed    
    
    
    
51. MAAHS DM, Svensson J
    Prevention of Cardiovascular Disease in Type 1 Diabetes.
    N Engl J Med. 2024;390:2226-2227.
    PubMed    
    
    
    
52. WENSTEDT EFE, Vogt L
    Prevention of Cardiovascular Disease in Type 1 Diabetes.
    N Engl J Med. 2024;390:2226.
    PubMed    
    
    
    
53. CHEN Y, Xu Y, Li H, Sun T, et al
    A Novel Anti-CD38 Monoclonal Antibody for Treating Immune Thrombocytopenia.
    N Engl J Med. 2024;390:2178-2190.
    PubMed     Abstract available
    
    
    May 2024
54. WECHSLER ME, Fan Y, Merkel PA
    Benralizumab versus Mepolizumab for Eosinophilic Granulomatosis with Polyangiitis. Reply.
    N Engl J Med. 2024;390:1940.
    PubMed    
    
    
    
55. SUN R, Wei LJ
    Benralizumab versus Mepolizumab for Eosinophilic Granulomatosis with Polyangiitis.
    N Engl J Med. 2024;390:1939.
    PubMed    
    
    
    
56. OIKONOMOU V, Smith G, Constantine GM, Schmitt MM, et al
    The Role of Interferon-gamma in Autoimmune Polyendocrine Syndrome Type 1.
    N Engl J Med. 2024;390:1873-1884.
    PubMed     Abstract available
    
    
    
57. SU MA
    JAK Inhibition Immunotherapy for APS-1.
    N Engl J Med. 2024;390:1918-1921.
    PubMed    
    
    
    
58. HENGEL FE, Dehde S, Lasse M, Zahner G, et al
    Autoantibodies Targeting Nephrin in Podocytopathies.
    N Engl J Med. 2024 May 25. doi: 10.1056/NEJMoa2314471.
    PubMed     Abstract available
    
    
    
59. WANG JJ, Schonborn L, Warkentin TE, Chataway T, et al
    Antibody Fingerprints Linking Adenoviral Anti-PF4 Disorders.
    N Engl J Med. 2024;390:1827-1829.
    PubMed    
    
    
    
60. DOUGHTY CT, Schaefer PW, Brizzi K, Linnoila JJ, et al
    Case 14-2024: A 30-Year-Old Woman with Back Pain, Leg Stiffness, and Falls.
    N Engl J Med. 2024;390:1712-1719.
    PubMed    
    
    
    
61. MULLER F, Mackensen A, Schett G
    CAR T-Cell Therapy in Autoimmune Disease. Reply.
    N Engl J Med. 2024;390:1631-1632.
    PubMed    
    
    
    
62. HOWARD JF JR, Vu T, Mozaffar T
    CAR T-Cell Therapy in Autoimmune Disease.
    N Engl J Med. 2024;390:1629-1631.
    PubMed    
    
    
    
63. DE BENEDETTI F, Diomedi Camassei F, Locatelli F
    CAR T-Cell Therapy in Autoimmune Disease.
    N Engl J Med. 2024;390:1629.
    PubMed    
    
    
    
64. MERKT W, Lorenz HM, Schmitt M
    CAR T-Cell Therapy in Autoimmune Disease.
    N Engl J Med. 2024;390:1628-1629.
    PubMed    
    
    
    April 2024
65. MATHUR M, Barratt J, Suzuki Y
    Phase 2 Trial of Sibeprenlimab in Patients with IgA Nephropathy. Reply.
    N Engl J Med. 2024;390:1245-1246.
    PubMed    
    
    
    
66. BELMONT HM
    Phase 2 Trial of Sibeprenlimab in Patients with IgA Nephropathy.
    N Engl J Med. 2024;390:1245.
    PubMed    
    
    
    
67. MANRIQUE-ACEVEDO C, Hirsch IB, Eckel RH
    Prevention of Cardiovascular Disease in Type 1 Diabetes.
    N Engl J Med. 2024;390:1207-1217.
    PubMed    
    
    
    March 2024
68. NETEA MG, van de Veerdonk FL
    Anti-Interleukin-23 Autoantibodies and Severe Infections.
    N Engl J Med. 2024;390:1143-1146.
    PubMed    
    
    
    
69. CHENG A, Kashyap A, Salvator H, Rosen LB, et al
    Anti-Interleukin-23 Autoantibodies in Adult-Onset Immunodeficiency.
    N Engl J Med. 2024;390:1105-1117.
    PubMed     Abstract available
    
    
    
70. DRIVENES JL, Bygum A
    Spontaneous Oral Purpura in Immune Thrombocytopenia.
    N Engl J Med. 2024;390:1029.
    PubMed    
    
    
    
71. WECHSLER ME, Nair P, Terrier B, Walz B, et al
    Benralizumab versus Mepolizumab for Eosinophilic Granulomatosis with Polyangiitis.
    N Engl J Med. 2024;390:911-921.
    PubMed     Abstract available
    
    
    February 2024
72. MULLER F, Taubmann J, Bucci L, Wilhelm A, et al
    CD19 CAR T-Cell Therapy in Autoimmune Disease - A Case Series with Follow-up.
    N Engl J Med. 2024;390:687-700.
    PubMed     Abstract available
    
    
    
73. ISAACS JD
    CAR T Cells - A New Horizon for Autoimmunity?
    N Engl J Med. 2024;390:758-759.
    PubMed    
    
    
    
74. HAUSER SL
    Silencing Immune Dialogue in Multiple Sclerosis.
    N Engl J Med. 2024;390:662-663.
    PubMed    
    
    
    
75. VERMERSCH P, Granziera C, Mao-Draayer Y, Cutter G, et al
    Inhibition of CD40L with Frexalimab in Multiple Sclerosis.
    N Engl J Med. 2024;390:589-600.
    PubMed     Abstract available
    
    
    January 2024
76. DANDONA P, Chaudhuri A, Ghanim H
    More on Semaglutide in Early Type 1 Diabetes. Reply.
    N Engl J Med. 2024;390:292.
    PubMed    
    
    
    
77. GAGLIA JL, Laffel LM, Patti ME
    More on Semaglutide in Early Type 1 Diabetes.
    N Engl J Med. 2024;390:291.
    PubMed    
    
    
    
78. WEINRAUCH LA, D'Elia JA
    More on Semaglutide in Early Type 1 Diabetes.
    N Engl J Med. 2024;390:291.
    PubMed    
    
    
    
79. DEVRIES JH
    More on Semaglutide in Early Type 1 Diabetes.
    N Engl J Med. 2024;390:290.
    PubMed    
    
    
    
80. HADZIC N, Deheragoda M, Worth A, Bansal S, et al
    JAK Inhibition in STAT1 Gain-of-Function-Mediated Treatment-Resistant Autoimmune Hepatitis.
    N Engl J Med. 2024;390:284-286.
    PubMed    
    
    
    
81. LEE TTM, Bergford S, Murphy HR
    Automated Insulin Delivery during Pregnancy Complicated by Type 1 Diabetes. Reply.
    N Engl J Med. 2024;390:184.
    PubMed    
    
    
    
82. GRZYCH G, Kim I
    Automated Insulin Delivery during Pregnancy Complicated by Type 1 Diabetes.
    N Engl J Med. 2024;390:183-184.
    PubMed    
    
    
    
83. VIVANTI AJ, Benachi A, Voican A
    Automated Insulin Delivery during Pregnancy Complicated by Type 1 Diabetes.
    N Engl J Med. 2024;390:183.
    PubMed    
    
    
    
84. LEMLEY KV, Glassock RJ
    APRIL - Springtime for New IgA Nephropathy Therapy?
    N Engl J Med. 2024;390:80-81.
    PubMed    
    
    
    
85. LIU MJ, Li J
    Necrobiosis Lipoidica.
    N Engl J Med. 2024;390:70.
    PubMed    
    
    
    December 2023
86. ARJUNAN D, Bhadada SK
    Thyroid Dermopathy in Graves' Disease.
    N Engl J Med. 2023;389:2376.
    PubMed    
    
    
    
87. LUDVIGSSON J
    Immune Interventions at Onset of Type 1 Diabetes - Finally, a Bit of Hope.
    N Engl J Med. 2023;389:2199-2201.
    PubMed    
    
    
    
88. WAIBEL M, Wentworth JM, So M, Couper JJ, et al
    Baricitinib and beta-Cell Function in Patients with New-Onset Type 1 Diabetes.
    N Engl J Med. 2023;389:2140-2150.
    PubMed     Abstract available
    
    
    November 2023
89. EL-ZAATARI ZM
    Anti-Glomerular Basement Membrane Glomerulonephritis.
    N Engl J Med. 2023;389:1901.
    PubMed    
    
    
    
90. BUSSEL JB, Hou M, Cines DB
    Primary Immune Thrombocytopenia in Pregnancy. Reply.
    N Engl J Med. 2023;389:1728.
    PubMed    
    
    
    
91. TRAN BW, May KA, Pal N
    Primary Immune Thrombocytopenia in Pregnancy.
    N Engl J Med. 2023;389:1728.
    PubMed    
    
    
    
92. MATHUR M, Barratt J, Chacko B, Chan TM, et al
    A Phase 2 Trial of Sibeprenlimab in Patients with IgA Nephropathy.
    N Engl J Med. 2023 Nov 2. doi: 10.1056/NEJMoa2305635.
    PubMed     Abstract available
    
    
    October 2023
93. RAMOS EL, Dayan CM, Chatenoud L, Sumnik Z, et al
    Teplizumab and beta-Cell Function in Newly Diagnosed Type 1 Diabetes.
    N Engl J Med. 2023 Oct 18. doi: 10.1056/NEJMoa2308743.
    PubMed     Abstract available
    
    
    
94. LINDHOFF-LAST E, Schonborn L, Zaninetti C, Warkentin TE, et al
    Rescue Therapy in Chronic Prothrombotic Autoimmune Anti-PF4 Disorder.
    N Engl J Med. 2023;389:1339-1341.
    PubMed    
    
    
    
95. SPIERA RF, Unizony S, Warrington KJ, Sloane J, et al
    Sarilumab for Relapse of Polymyalgia Rheumatica during Glucocorticoid Taper.
    N Engl J Med. 2023;389:1263-1272.
    PubMed     Abstract available
    
    
    
96. LEE TTM, Collett C, Bergford S, Hartnell S, et al
    Automated Insulin Delivery in Women with Pregnancy Complicated by Type 1 Diabetes.
    N Engl J Med. 2023 Oct 5. doi: 10.1056/NEJMoa2303911.
    PubMed     Abstract available
    
    
    
97. GARG SK, Polsky S
    Technology Use and Glycemic Outcomes during Pregnancy with Type 1 Diabetes.
    N Engl J Med. 2023 Oct 5. doi: 10.1056/NEJMe2310798.
    PubMed    
    
    
    
98. ALETAHA D
    Polymyalgia Rheumatica - from Search for Efficacy to Choice of Strategy.
    N Engl J Med. 2023;389:1328-1329.
    PubMed    
    
    
    September 2023
99. BRODERICK L, Kastner DL
    Variant STAT4 and Treatment of an Autoinflammatory Syndrome. Reply.
    N Engl J Med. 2023;389:1151-1152.
    PubMed    
    
    
    
100. PASTORE S, De Martino E, Taddio A
     Variant STAT4 and Treatment of an Autoinflammatory Syndrome.
     N Engl J Med. 2023;389:1151.
     PubMed    
     
     
     
101. WANG WY, Cheng ST
     Sleeve Sign and Inverse Gottron's Papules in Anti-MDA5 Dermatomyositis.
     N Engl J Med. 2023;389:1032.
     PubMed    
     
     
     
102. DANDONA P, Chaudhuri A, Ghanim H
     Semaglutide in Early Type 1 Diabetes.
     N Engl J Med. 2023;389:958-959.
     PubMed    
     
     

Thank you for your interest in scientific medicine.

AMEDEO Autoimmune Disorders is free of charge.